IP Library › Granted Patent US 9,102,722
Granted Patent B2
US 9,102,722 · App. 14/033,707 · Granted Aug 11, 2015

Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,722
App. No.
14/033,707
Granted
Aug 11, 2015
Kind
B2
Abstract

Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Claims (8)

1. An isolated antibody the antibody comprising:

(a) a variable heavy domain comprising a complementarity-determining region (CDR) 1 comprising an amino acid sequence as set forth in SEQ ID NO:2, a CDR2 comprising an amino acid sequence as set forth in SEQ ID NO:3, and a CDR3 comprising an amino acid sequence as set forth in SEQ ID NO:4, and a variable light domain comprising a CDR1 comprising an amino acid sequence as set forth in SEQ ID NO:6, a CDR2 comprising an amino acid sequence as set forth in SEQ ID NO:7, and a CDR3 comprising an amino acid sequence as set forth in SEQ ID NO:73; or

(b) a light chain variable amino acid sequence as set forth in SEQ ID NO:146 and a heavy chain variable amino acid sequence as set forth in SEQ ID NO:147,

wherein the antibody binds to Repulsive Guidance Molecule a (RGMa), wherein the antibody is selected from the group consisting of a human antibody, a monoclonal antibody, an affinity matured, a chimeric antibody and a humanized antibody.

2. The isolated antibody of claim 1 , further comprising a constant sequence of SEQ ID NO:143.

3. A pharmaceutical composition comprising the antibody of claim 1 .

4. A pharmaceutical composition comprising the antibody of claim 2 .

5. The isolated antibody of claim 1 , wherein the variable heavy domain comprises the CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:2, the CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:3, and the CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:4, and the variable light domain comprises the CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:6, the CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:7, and the CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:73.